Board of Directors
Roderick Carter, MD
Chairman of the Board
Dr. Roderick Carter has a strong history of contributions to healthcare through clinical, research, business and people leadership. He has significant experience developing and commercializing nutraceutical and pharmaceutical products and has successfully led clinical research and business development strategies for cardiovascular and inflammation related diseases. Dr. Carter is currently Principal at Aquila Life Sciences LLC, a consulting firm he founded in April 2008 focusing on pharmaceutical development and commercialization. Prior to this he was Vice President of Clinical Development at Reliant Pharmaceuticals, which developed the omega-3 cardiovascular drug Lovaza, and today is a wholly owned subsidiary of GlaxoSmithKline. He also served as Executive Director at Merck and Co., USA, President and Chief Executive Officer of WellGen and Senior Medical Director at Pfizer Inc., USA. Dr. Carter received his Medical Degree from the University of Witwatersrand, Johannesburg, along with a Master of Science degree in Sports Medicine from Trinity College, Dublin.
Jan D’Alvise is the President and CEO of Acasti Pharma Inc. She has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Previously, Ms. D’Alvise was the President and Chairman of Pediatric Bioscience and before that, the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. D’Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute. From 1995, she was also the Co-Founder and Executive VP/COO of Metrika Inc. (which was acquired by Bayer), and in 1999 was the Co-Founder/President/CEO/Chairman of NuGEN, Inc. Ms. D’Alvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. D’Alvise was a VP of Drug Development at Syntex/Roche and Business Unit Director of the Pain and Inflammation business. Prior to Syntex, Ms. D’Alvise was the VP of Commercial Operations at SYVA, (Syntex’s clinical diagnostics division), and she began her career with Diagnostic Products Corporation (DPC). Ms. D’Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post-graduate work at the University of Michigan, Stanford University, and the Wharton Business School. Ms. D’Alvise has served on the boards of numerous private and non-profit companies, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship at the University of California, San Diego.
Leendert H. Staal, Ph.D.